Candidate Program Cand Prog
Indication Target Class Ind Target
Discovery Discov
Phase 1 Ph 1
Phase 2 Ph 2
Pivotal
Trial
Pivotal
Partner Ptr
OKI-179
NRAS Melanoma Combo w/Binimetinib
OKI-179
NRAS Melanoma Combo w/Binimetinib
Pfizer logo
Class-1 HDAC inhibition has been shown to dramatically enhance the efficacy of MEK inhibitors in Ras pathway driven melanomas by coordinately suppressing two DNA repair pathways. A potential clinical biomarker that predicts responsiveness has also been identified.

Discovery

Candidate Program Cand Prog
Indication Target Class Ind Target
Discovery Discov
Phase 1 Ph 1
Phase 2 Ph 2
Pivotal
Trial
Pivotal
Partner Ptr
ONK-001
Kinase Target
ONK-001
Kinase Target
ONK-002
Kinase Target
ONK-002
Kinase Target
ONK-003
Kinase Target
ONK-003
Kinase Target
ONK-004
Kinase Target
ONK-004
Kinase Target
ONK-005
Non-Kinase Target
ONK-005
Non-Kinase Target
ONK-006
Non-Kinase Target
ONK-006
Non-Kinase Target